These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 16382976

  • 1. [Breast cancer: HER2 changes one's cards on the table].
    Lopez M.
    Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
    [Abstract] [Full Text] [Related]

  • 2. [Role of taxanes in treatment of breast cancer].
    Gorbunova VA, Besova NS.
    Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
    [No Abstract] [Full Text] [Related]

  • 3. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J.
    Lancet; 2010 Jan 30; 375(9712):377-84. PubMed ID: 20113825
    [Abstract] [Full Text] [Related]

  • 4. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S, Di Lauro L, Sergi D, Foggi P, Perri P, Tirelli C, Mottolese M, Fattoruso SI, Lopez M.
    Clin Ter; 2008 Jan 30; 159(6):449-52. PubMed ID: 19169607
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
    Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN.
    Clin Cancer Res; 2007 Jan 01; 13(1):228-33. PubMed ID: 17200359
    [Abstract] [Full Text] [Related]

  • 6. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet Oncol; 2011 Mar 01; 12(3):236-44. PubMed ID: 21354370
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J, Perez EA, Pienkowski T, Bell R.
    Oncologist; 2006 Mar 01; 11 Suppl 1():4-12. PubMed ID: 16971734
    [Abstract] [Full Text] [Related]

  • 8. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N.
    Lancet Oncol; 2013 Nov 01; 14(12):1183-92. PubMed ID: 24095300
    [Abstract] [Full Text] [Related]

  • 9. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
    Nabholtz JM, Reese DM, Lindsay MA, Riva A.
    Clin Breast Cancer; 2002 Oct 01; 3 Suppl 2():S75-9. PubMed ID: 12435291
    [Abstract] [Full Text] [Related]

  • 10. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato P, Crinó L, Agostara B, Conte P.
    Clin Breast Cancer; 2008 Oct 01; 8(5):453-6. PubMed ID: 18952561
    [Abstract] [Full Text] [Related]

  • 11. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
    Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N.
    J Clin Oncol; 2011 Sep 01; 29(25):3366-73. PubMed ID: 21768458
    [Abstract] [Full Text] [Related]

  • 12. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.
    J Clin Oncol; 2011 Sep 01; 29(25):3351-7. PubMed ID: 21788566
    [Abstract] [Full Text] [Related]

  • 13. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N.
    N Engl J Med; 2005 Oct 20; 353(16):1673-84. PubMed ID: 16236738
    [Abstract] [Full Text] [Related]

  • 14. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
    Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN.
    J Clin Oncol; 2005 Jun 01; 23(16):3676-85. PubMed ID: 15738535
    [Abstract] [Full Text] [Related]

  • 15. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J.
    Lancet Oncol; 2014 Sep 01; 15(10):1137-46. PubMed ID: 25130998
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
    Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, Murakami S, Yamamoto Y, Kashiwaba M, Iwata H, Uemura Y, Ohashi Y.
    Jpn J Clin Oncol; 2011 May 01; 41(5):709-12. PubMed ID: 21355003
    [Abstract] [Full Text] [Related]

  • 17. [Adjuvant chemotherapy for breast cancer and targeted therapies].
    Dufresne A, Bachelot T, Blay JY.
    Rev Prat; 2008 Mar 15; 58(5):477-8. PubMed ID: 18524101
    [No Abstract] [Full Text] [Related]

  • 18. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
    Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP.
    J Clin Oncol; 2003 Jan 01; 21(1):46-53. PubMed ID: 12506169
    [Abstract] [Full Text] [Related]

  • 19. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J.
    Oncology; 2001 Jan 01; 61 Suppl 2():14-21. PubMed ID: 11694783
    [Abstract] [Full Text] [Related]

  • 20. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL.
    J Clin Oncol; 2009 Dec 01; 27(34):5685-92. PubMed ID: 19884557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.